On Tuesday, September 29, 2026, ASCA Corporation ("ASCA") co-hosted an online seminar with ProductLife Japan K.K. titled "Ensuring Success in the Pharmaceutical Business After EMA Approval: A Perspective on Market and Patient Access "
On the day, Alberto Rubio of ProductLife Group addressed pharmaceutical and biotech companies considering entry into the European market, explaining the market access strategies required after EMA approval and the differences in pricing and reimbursement systems between countries.
This article shares the key takeaways from the webinar.
In Europe, the real challenge begins after approval
When considering expansion into Europe, many companies focus first on obtaining approval from the EMA (European Medicines Agency). However, a point emphasized repeatedly in this seminar was that "EMA approval is not the goal, but merely the starting line."
In Europe, several important processes still lie ahead after approval:
- Pricing negotiations in each country
- Reimbursement applications
- HTA (Health Technology Assessment)
- Hospital adoption (formulary listing)
In recent years, responding to the JCA (Joint Clinical Assessment), which aims to harmonize HTA assessments within the EU, has also become important. Under the JCA, a common EU-level assessment of the clinical usefulness of new medicines is conducted, and the results are used as a basis for HTA and reimbursement reviews in each country. Building an evidence strategy with the JCA in mind from the development stage therefore leads to smooth access to the European market.
.png)
While EU member states share a common regulatory framework, each country decides its own pricing and reimbursement systems. It was therefore explained that obtaining EMA approval alone does not guarantee market entry, and that a country-by-country market access strategy is essential.
Europe is not a single market
The lecture also explained how pricing and reimbursement assessments differ between countries.
For example, there are:
- Countries that emphasize cost-effectiveness
- Countries that emphasize additional clinical benefit
- Countries that consider budget impact and regional characteristics in addition to clinical value
As these examples show, the perspective of assessment differs greatly from country to country. Therefore, even with the same clinical data or evidence package, the assessment results and the approach to price negotiations may vary from market to market.
The key message of the lecture was that "rather than viewing Europe as a single market, it is important to understand it as a collection of multiple markets."
Growing interest in the MFN (Most Favored Nation) policy
During the Q&A session, a question was also raised about the US MFN (Most Favored Nation) policy.
The responses and initiatives of European countries, which are particularly susceptible to the effects of international reference pricing, were also introduced, and participants commented that the content was "extremely meaningful."
A message from the speaker, Alberto Rubio
The message Mr. Rubio most wanted to convey in this seminar can be summed up as follows:
"Starting preparations after submitting to the EMA is too late. If you are aiming to enter Europe, you should prepare in advance with the JCA in mind."
Success in the European market requires not only regulatory compliance but also a market access strategy built with the post-approval phase in mind. Rather than treating EMA approval as the goal, preparing for what lies beyond it, namely pricing, reimbursement and HTA, is a key factor in the success or failure of a European business.
We hope this report proves useful to those considering expansion into Europe, as well as to those who have already entered Europe and are facing challenges.
About ASCA Corporation
ASCA provides translation and interpreting, medical writing, and AI translation solutions in the life sciences field. In addition to supporting global communication in the pharmaceutical industry, ASCA supports the multilingual needs that arise from multinational clinical trials and overseas regulatory submissions. Drawing on this experience, ASCA co-hosted this webinar with ProductLife Japan, focusing on the practicalities of the post-EMA-approval phase.
Contact
株式会社アスカコーポレーション 営業部
aiko.scilingual@asca-co.com


